Το Πανεπιστημιακό Γενικό Νοσοκομείο Πατρών «Παναγία η Βοήθεια» είναι ελληνικό πανεπιστημιακό γενικό δημόσιο νοσοκομείο στο Ρίο Αχαΐας. Βρίσκεται πλησίον της πανεπιστημιούπολης του Πανεπιστημίου Πατρών και απέχει οδικώς 9 χιλιόμετρα περίπου από το κέντρο της πόλης της Πάτρας.

During the past decade, University General Hospital of Patras conducted 86 clinical trials. In the 10-year time frame, 86 clinical trials started and 39 clinical trials were completed, i.e. on average, 45.3% percent of trials that started reached the finish line to date. In the past 5 years, 42 clinical trials started and 31 clinical trials were completed. i.e. 73.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University General Hospital of Patras" #1 sponsor was "Celgene" with 10 trials, followed by "University of Patras" with 7 trials sponsored, "Bayer" with 6 trials sponsored, "Shire" with 6 trials sponsored and "Hoffmann-La Roche" with 6 trials sponsored. Other sponsors include 69 different institutions and companies that sponsored additional 53 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University General Hospital of Patras" #1 collaborator was "Janssen Research & Development, LLC" with 3 trials as a collaborator, "Takeda Development Center Americas, Inc." with 3 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 2 trials as a collaborator, "Sanofi" with 2 trials as a collaborator and "Amgen" with 1 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "University General Hospital of Patras" are "Multiple Myeloma" (10 trials), "Idiopathic Pulmonary Fibrosis" (5 trials), "Crohn's Disease" (4 trials), "Breast Cancer" (3 trials) and "Follicular Lymphoma" (3 trials). Many other conditions were trialed in "University General Hospital of Patras" in a lesser frequency.

Most popular intervention types in "University General Hospital of Patras" are "Drug" (85 trials), "Other" (13 trials), "Biological" (5 trials), "Device" (4 trials) and "Procedure" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (27 trials), "Dexamethasone" (11 trials), "Bortezomib" (5 trials), "Carboplatin" (5 trials) and "Lenalidomide" (5 trials). Other intervention names were less common.

The vast majority of trials in "University General Hospital of Patras" are 102 trials for "All" genders, 3 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "University General Hospital of Patras". 2 are not yet recruiting, 20 are recruiting, 22 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 46 completed trials in University General Hospital of Patras, undefined suspended trials, and 15 terminated clinical trials to date.

Out of the total trials that were conducted in University General Hospital of Patras, 2 "Phase 1" clinical trials were conducted, 33 "Phase 2" clinical trials and 53 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 3 trials that are defined as “Not Applicable".